Glimepiride Metformin Bilayered Smart Tablet in pharma franchise in Kerala

Glimepiride Metformin Bilayered Smart Tablet in PCD pharma franchise in Aizawl

Glimepiride Metformin Bilayered Smart Tablet in top pharma company in Agartala

Glimepiride Metformin Bilayered Smart Tablet in pcd pharma supplier in Maharashtra

Glimepiride Metformin Bilayered Smart Tablet in phama franchise company in india
Glimepiride Metformin Bilayered Smart Tablet in phama distributor in Tamil Nadu

Home/Products /glimepiride-2mg-metformin-500mg-sr-bilayered-smart-tablet

Gimtype M2 Tablet

Composition : Glimepiride (2mg) + Metformin (500mg) SR Bilayered Smart Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*15

Price : ₹111/-

Gimtype M2 Tablet is a bilayered smart formulation combining Glimepiride 2mg and Metformin 500mg in a sustained-release form. Designed to optimize glycemic control, this dual-action oral antidiabetic therapy targets multiple mechanisms involved in type 2 diabetes management. Glimepiride, a sulfonylurea, enhances insulin secretion from pancreatic beta cells, helping reduce fasting and postprandial blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose output. The bilayered design of Gimtype M2 allows for controlled and extended release of Metformin, ensuring better gastrointestinal tolerance and more consistent blood glucose control throughout the day. This smart tablet is ideal for patients who require a more intensive glycemic management plan without increasing the pill burden.

Read More

About the Product

Gimtype M2 Tablet is a bilayered smart formulation combining Glimepiride 2mg and Metformin 500mg in a sustained-release form. Designed to optimize glycemic control, this dual-action oral antidiabetic therapy targets multiple mechanisms involved in type 2 diabetes management. Glimepiride, a sulfonylurea, enhances insulin secretion from pancreatic beta cells, helping reduce fasting and postprandial blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose output. The bilayered design of Gimtype M2 allows for controlled and extended release of Metformin, ensuring better gastrointestinal tolerance and more consistent blood glucose control throughout the day. This smart tablet is ideal for patients who require a more intensive glycemic management plan without increasing the pill burden.

Some patients may experience mild side effects such as nausea, abdominal discomfort, diarrhea, or dizziness. Hypoglycemia may occur, particularly if the tablet is taken without adequate food. Rare but serious risks include lactic acidosis, especially in those with renal impairment. It is important to take this medicine exactly as prescribed and report any adverse symptoms to a healthcare provider.

Gimtype M2 Tablet is indicated for adults with type 2 diabetes mellitus when lifestyle modifications and monotherapy with either Glimepiride or Metformin do not provide sufficient glycemic control. It helps reduce both fasting and post-meal blood glucose levels.

Not recommended for patients with significant renal or hepatic impairment, heart failure, or metabolic acidosis. Caution is advised in elderly patients and during times of stress such as surgery or infection. Avoid alcohol consumption while on this medication.

Store below 30°C in a dry and cool place. Protect from direct sunlight and moisture. Keep the container tightly closed and out of the reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation